Home » Topics » BioWorld Science

BioWorld Science
RSS

Antibe reports secondary endpoint data from phase IIb GI safety study of ATB-346

July 5, 2018

Mitsubishi Tanabe studies MT-7117 in phase II for erythropoietic protoporphyria

July 5, 2018

TLR7 agonists presented by Apros Therapeutics

July 5, 2018

Roche initiates phase I study of RO-7172508 in CEA-positive solid tumors

July 5, 2018

Sumitomo Dainippon seeks Japanese approval for thiotepa as pre-HSCT conditioning treatment

July 5, 2018

Shenzhen Targetrx Biotechnology presents EGFR mutant inhibitors

July 5, 2018

Sanofi and Lead Pharma Holding patent RORC modulators

July 5, 2018

Celtaxsys divulges new LTA-4 hydrolase inhibitors

July 5, 2018

Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news

July 5, 2018

New Era Pharma presents Sgk1 and/or Sgk2 inhibitors

July 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...